ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

AbbVie acquires Mavupharma, developer of small molecules that activate STING

by Ryan Cross
July 19, 2019 | APPEARED IN VOLUME 97, ISSUE 29

AbbVie has acquired Mavupharma, a small Seattle-based biotech company, for an undisclosed sum. Mavupharma’s lead candidate is an inhibitor of an enzyme called ENPP1. Inhibiting that enzyme increases the activity of another protein known as STING, which itself enhances the innate immune system. The goal is to boost the efficacy of existing cancer immunotherapies. Several drug companies are trying to activate STING directly, which often requires injecting a drug into tumors. Mavupharma’s small molecule has the advantage of potentially being a pill.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment